Key Laboratory for Green Pharmaceutical Technologies and Related Equipment of Ministry of Education, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China.
Magn Reson Chem. 2014 Apr;52(4):178-82. doi: 10.1002/mrc.4048. Epub 2014 Jan 27.
Spectroscopic tools such as NMR can be applied to the quantitative analysis of active pharmaceutical ingredients with relative ease and accuracy. Here, we demonstrate the quantification of clindamycin phosphate (CLP) in a conventional tablet formulation, performed using potassium hydrogen phthalate (KHP) as the internal standard and deuterium oxide (D2O) as the NMR solvent. The methyl protons signal of CLP at 0.72 ppm (triplet) relative to the signal of KHP at 7.37-7.40 ppm (multiplet) was used for quantification purposes using (1)H NMR. This method was shown to be specific and linear (r = 0.9997) within the CLP concentration range from 7.2 to 23.1 mg per 0.5 ml of D2O. The maximum relative standard deviation (RSD) of accuracy and precision was calculated at 0.39% and 0.64%, respectively. The limits of detection (LOD) and quantification were 0.04 and 0.11 mg/ml, respectively. The method was highly stable with a calculated RSD of 0.03%. The robustness of the method was demonstrated by changing four different parameters, and the difference among each parameter was ≤ 0.78%. The findings of this work were in good agreement with previously reported conventional HPLC-based approaches, highlighting its applicability in the determination of other active pharmaceutical ingredients in conventional formulations for quality control purposes.
光谱学工具,如 NMR,可以相对容易和准确地应用于活性药物成分的定量分析。在这里,我们展示了使用邻苯二甲酸氢钾(KHP)作为内标和重水(D2O)作为 NMR 溶剂,对常规片剂制剂中的克林霉素磷酸酯(CLP)进行定量的方法。使用(1)H NMR,通过将 CLP 的 0.72 ppm 处的甲基质子信号(三重峰)与 KHP 的 7.37-7.40 ppm 处的信号(多重峰)进行相对定量。该方法在 7.2 至 23.1 mg/0.5 ml D2O 范围内表现出特异性和线性(r = 0.9997)。准确度和精密度的最大相对标准偏差(RSD)分别计算为 0.39%和 0.64%。检测限(LOD)和定量限分别为 0.04 和 0.11 mg/ml。该方法具有高度稳定性,计算的 RSD 为 0.03%。通过改变四个不同的参数来证明方法的稳健性,每个参数之间的差异≤0.78%。这项工作的结果与先前报道的基于常规 HPLC 的方法一致,突出了其在常规制剂中用于其他活性药物成分的质量控制目的的适用性。